Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

Queens University spin-out Re-Vana Therapeutics has agreed a $1bn deal with biopharma giant Boehringer Ingelheim.

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

The total value of the deal exceeds $1bn for the first three targets, in addition to royalty payments based on net sales.

Family-owned Boehringer Ingelheim, now Germany’s largest drugmaker by revenue, has reported positive growth in the first half ...

The clinical benefits of exercise-based cardiac rehabilitation have been less clear for patients with Afib. A meta-analysis ...

BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.

Learn about the ongoing battle against Marek's disease, its immunosuppressive effects, and cutting-edge vaccine technologies protecting broiler health.

Market is set to experience robust expansion, growing from an estimated USD 2.4 billion in 2025 to USD 4.2 billion by 2035, ...

In terms of drug class, immunosuppressants hold the largest market share, accounting for 42.10% in 2024. Their effectiveness ...